Corticosteroid weaning late after heart transplantation: relation to HLA-DR mismatching and long-term metabolic benefits.
BACKGROUND
To avoid the long-term side effects of corticosteroids, corticosteroid-free immunosuppression has been introduced immediately or late (more than 6 months) after heart transplantation. Late corticosteroid weaning may have a higher success rate as patients are selected on the basis of rejection history. Previous reports of HLA-DR mismatching and the long-term metabolic benefits with respect to corticosteroid weaning have been equivocal.


METHODS
One hundred and one eligible heart transplant recipients receiving triple-drug immunosuppression 6 months from heart transplantation were weaned from prednisone by decreasing the daily prednisone dose by 1 mg each month. Moderate rejection episodes were recorded and after conclusion of the study, HLA-DR mismatching of recipient and donor was reviewed. Serum cholesterol level, body weight, and number of patients receiving blood pressure medications were recorded before and 1 year after corticosteroid weaning.


RESULTS
Successful weaning from corticosteroids was achieved in 82% of patients. Of 31 patients with zero or one HLA-DR mismatch, 30 (97%) were successfully weaned. For those patients more than 1 year after discontinuation of corticosteroids, 67 had more weight loss and a lower serum cholesterol level than 15 patients who were unsuccessful at corticosteroid weaning and dependent on corticosteroids.


CONCLUSIONS
Heart transplant recipients can safely be weaned from corticosteroids late after heart transplantation with zero or one HLA-DR mismatch conferring a higher success rate. The long-term metabolic benefits of corticosteroid weaning include a reduction in weight and serum cholesterol.
Kobashigawa
J A
JA
Division of Cardiology and Cardiothoracic Surgery UCLA School of Medicine, USA.
Stevenson
L W
LW
Brownfield
E D
ED
Gleeson
M P
MP
Moriguchi
J D
JD
Kawata
N
N
Minkley
R
R
Drinkwater
D C
DC
Laks
H
H
D001835:Body Weight; D002784:Cholesterol / Q000097:blood*; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006684:HLA-DR Antigens / Q000032:analysis*; D016027:Heart Transplantation; D006648:Histocompatibility; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D011241:Prednisone / Q000008:administration & dosage*; D013997:Time Factors
D006684:HLA-DR Antigens; D007166:Immunosuppressive Agents; D002784:Cholesterol; D011241:Prednisone